With an increasing number of clinical trials ongoing, and initial clinical results from first-generation agonists enabling the industry to better understand the mechanisms of the targets, scientists are calling for more mechanistic understanding of the target biology to design the optimal formats.

The 2nd Annual Agonist Immunotherapy Targets conference will showcase the expanding formats and design principles to approach these agonist targets and pathways; discuss strategies to enhance specificity and reduce toxicity; and present the latest updates and lessons learned from molecules in the clinic.  

Coverage will include, but is not limited to:

  • Mechanistic Understanding of the Targets
    • How these signal complexes organize?
    • How molecules interact?
    • Distribution and delivery of the molecules
    • How does the desired agonist MOA and target biology impact discovery strategy?
    • How to determine the optimal format (ligand-fusion, Fc-modified, bispecific etc) of the final candidate?
  • Formats and Approaches Toward Agonist Targets and Pathways
    • 4-1BB, OX40, CD40, ICOS, Cytokines, IL2, TLR, TNR-SF, GITR, STING, LIGHT, TRAIL, Oncolytic Viruses
  • Molecules in the Clinic – Monotherapy and Combination Therapies
    • 4-1BB, OX40, CD40, ICOS, TLR, Oncolytic viruses etc - how much activity is happening/not happening?
    • What’s happening in the tumor microenvironment?
    • Enhancing specificity and reducing toxicity of the agonists in the tumor microenvironment
    • Controlling specific activity of immune cells in tumor context
    • Balancing activity and toxicity
  • Mouse in vivo Data of Single vs Combination Studies
    • Is the in vitro data translating to in vivo?
    • How to evaluate agonists that lack mouse cross-reactivity?


If you would like to submit a proposal to give a presentation at this meeting, please CLICK HERE.

The deadline for priority consideration is 26 April 2019.

All proposals are subject to review by session chairmen and/or the Scientific Advisory Committee to ensure the overall quality of the conference program. Additionally, as per Cambridge Healthtech Institute’s policy, a select number of vendors and consultants who provide products and services will be offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.

For more details on the conference, please contact:
Mimi Langley
Senior Conference Director
Cambridge Healthtech Institute
Phone: (+1) 781. 972.5439
Email: mlangley@healthtech.com

For partnering and sponsorship information, please contact:

Companies A-K
Jason Gerardi
Senior Manager, Business Development
Cambridge Healthtech Institute
Phone: (+1) 781.972.5452
Email: jgerardi@healthtech.com

Companies L-Z
Ashley Parsons
Manager, Business Development
Cambridge Healthtech Institute
Phone: (+1) 781.972.1340
Email: ashleyparsons@healthtech.com